JOSE RAMIRO LAGUNA / SHUTTERSTOCK.COM
Which patented drugs are losing their market exclusivity in 2015, and how will their makers cope? LSIPR takes a look at five of the biggest drugs to lose patent protection in the US this year.
The small molecules cliff will soon make way for the biologics cliff—a phenomenon that is predicted to come into effect around 2020—but before then, here are five drugs that will lose US patent protection this year, possibly having a major impact on their makers.
Gleevec (imatinib)
Patent expired on January 4
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
patent, Gleevec, Sanofi, Actavis, Avodart, Otsuka. Namenda